Divis Laboratories, a leading player in the pharmaceutical and biotechnology sectors, is headquartered in Hyderabad, India. Founded in 1990, the company has established itself as a prominent manufacturer of active pharmaceutical ingredients (APIs) and intermediates, catering to a global clientele. With a strong focus on research and development, Divis Laboratories has achieved significant milestones, including the successful launch of several high-quality products that meet stringent regulatory standards. The company’s core offerings include APIs for various therapeutic areas, particularly in anti-retroviral and anti-cancer medications, which are distinguished by their purity and efficacy. Divis Laboratories is recognised for its robust market position, consistently ranking among the top suppliers in the industry. Its commitment to innovation and sustainability further enhances its reputation as a trusted partner in the pharmaceutical landscape.
How does Divis Laboratories's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Divis Laboratories's score of 46 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Divis Laboratories reported total greenhouse gas emissions of approximately 363,246,000 kg CO2e for Scope 1 and about 325,972,000 kg CO2e for Scope 2. This reflects a slight decrease from 2023, where emissions were approximately 380,676,000 kg CO2e for Scope 1 and about 373,141,000 kg CO2e for Scope 2. The company has not disclosed any Scope 3 emissions data. Divis Laboratories has set ambitious climate commitments, aiming for a 25% reduction in intensity-based greenhouse gas emissions (Scope 1 and 2) by 2030, with a base year of 2023. Furthermore, the company has committed to achieving net-zero greenhouse gas emissions across its value chain by 2050. Near-term targets include a significant reduction of 58.8% in absolute Scope 1 and 2 emissions by FY2034, alongside a 35% reduction in absolute Scope 3 emissions within the same timeframe. These targets align with the Science Based Targets initiative (SBTi) and are consistent with the reductions required to limit global warming to 1.5°C. The long-term goal includes a 90% reduction in both Scope 1 and 2 emissions by 2050, as well as a 90% reduction in Scope 3 emissions. Divis Laboratories is actively working towards these goals, demonstrating a strong commitment to sustainability and climate action.
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 382,670,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 370,742,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Divis Laboratories has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Common questions about Divis Laboratories's sustainability data and climate commitments